Medications through injections for managing psoriatic arthritis symptoms
In the management of psoriatic arthritis (PsA), a type of inflammatory arthritis that can affect a person's joints, injectable medications may be recommended for those experiencing moderate to severe symptoms. These treatments, which primarily belong to a group of medications known as biologics, can help relieve symptoms and prevent joint damage.
When determining the best type of injectable medication for an individual patient with PsA, several key factors are considered.
Firstly, disease severity and manifestations play a significant role. Patients with mild disease who have an inadequate response to conventional synthetic disease-modifying antirheumatic drugs (csDMARDs) might be considered for PDE4 inhibitors. On the other hand, those with more severe manifestations such as enthesitis, axial disease, or rapidly progressing polyarthritis may require biologic DMARDs (bDMARDs) or Janus kinase inhibitors (JAKi).
The choice of injectable therapy often reflects accompanying non-musculoskeletal symptoms, especially skin involvement. For example, if significant skin psoriasis is present, preference may be given to inhibitors targeting interleukin (IL)-17A, IL-17A/F, IL-23, or IL-12/23 pathways because they effectively treat both joint and skin symptoms.
The patient's history with conventional agents such as methotrexate, cyclosporine, sulfasalazine, and leflunomide is critical. Injectable biologics like abatacept (Orencia®) are considered when there is inadequate response, intolerance, or contraindications to these conventional therapies.
Safety profiles impact selection. For example, systemic glucocorticoids are used cautiously due to potential adverse effects, while local glucocorticoid injections may be added as adjunctive therapy. Comorbid conditions like inflammatory bowel disease can influence the choice since certain biologics have indications for both PsA and associated conditions (e.g., IL-12/IL-23 inhibitors for Crohn’s disease).
Practical considerations such as convenience, dosing frequency, and patient preference between subcutaneous injections and intravenous infusions also play roles in selection. For example, abatacept is available by both IV and subcutaneous routes with weight-based dosing, and IL-12/23 inhibitors like guselkumab (Tremfya) have specific subcutaneous regimens that may appeal to certain patients for ease of use.
Guided by up-to-date clinical recommendations and expert consensus, selecting the best injectable therapy for PsA involves an integrated assessment of disease characteristics, treatment history, safety profile, comorbidities, administration routes, and patient preferences.
Discussing the risks and potential benefits of injectable medications with a doctor is essential for anyone with PsA considering this treatment option. The Food and Drug Administration (FDA) has approved several biologics for the treatment of moderate to severe PsA.
It is important to note that other treatments for PsA, including nonsteroidal anti-inflammatory drugs, traditional disease-modifying antirheumatic drugs, short courses of oral corticosteroids, physical or occupational therapies, low-impact exercise, and joint support with splints or braces, may be recommended before injectable medications.
Injections can be administered intravenously or subcutaneously, with self-administration possible for some subcutaneous injections. A doctor might recommend injectable treatments for moderate to severe PsA, plaque psoriasis, or PsA that has not responded well to other treatments.
Injections do not cure the underlying cause, requiring ongoing treatment. The frequency of injections depends on the type of medication and is adjusted by a doctor according to each case. Regular checkups are necessary for those using injectable medications to screen for infections and other potential harmful effects.
Intra-articular injections may be used to administer corticosteroids directly into an affected joint. Biologics target specific cells or proteins in the immune system, such as T cells, TNF-alpha, IL-17, IL-12, and IL-23.
For more information about PsA treatments, readers are encouraged to consult resources such as the Arthritis Foundation.
- In the management of psoriatic arthritis (PsA), a person's joint condition, disease severity, and manifestations are crucial factors in deciding the best type of injectable medication.
- Patients with mild PsA who have not responded well to conventional synthetic disease-modifying antirheumatic drugs (csDMARDs) might be considered for PDE4 inhibitors.
- Those with more severe PsA manifestations, such as enthesitis, axial disease, or rapidly progressing polyarthritis, may require biologic DMARDs (bDMARDs) or Janus kinase inhibitors (JAKi).
- Inhibitors targeting interleukin (IL)-17A, IL-17A/F, IL-23, or IL-12/23 pathways could be preferred for patients with significant skin psoriasis due to their effectiveness in treating both joint and skin symptoms.
- A patient's history with conventional agents, such as methotrexate, cyclosporine, sulfasalazine, and leflunomide, plays a significant role in the choice of injectable biologics.
- Certain biologics like abatacept (Orencia®) are considered when there is inadequate response, intolerance, or contraindications to conventional therapies.
- The safety profiles of various injectable therapies impact the selection process, with systemic glucocorticoids being used cautiously due to potential adverse effects.
- For patients with PsA considering injectable medications, it is essential to discuss the risks and potential benefits with a doctor since the Food and Drug Administration (FDA) has approved several biologics for the treatment of moderate to severe PsA.
